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Introduction: the need to reproduce human cancer in
the mouse
The dilemma of current cancer therapies is that, although most
cancer patients respond to therapy, only a few are definitely cured
(Etzioni et al., 2003). Current cancer therapies are designed to target
proliferating tumor cells. Although such strategies eliminate the
visible portion of the tumor, namely the tumor mass, they mostly
fail to eliminate the unseen root of cancer (Sanchez-Garcia et al.,
2007). In order to study and accurately solve the complex host-
tumor interactions that occur during tumor development, it is
necessary to perform experiments in an in vivo setting in which
the neoplasm emerges in the appropriate microenvironment.
Research in mice integrates the complexity of the organs and their
different cell types within the context of the global physiological
status of the organism. Certain strains of mice develop cancer
spontaneously (Hardisty, 1985). However, such models develop a
restricted subset of tumor types that do not reflect the common
forms of human cancer and do not allow the systematic
investigation of tumor genetics and gene-environment interactions.
Since the discovery that human tumors contain activated oncogenes
(Fig. 1A), many efforts have been made to develop organ-specific
cancer mouse models where tumors arise from normal cells that
are resident in their natural tissue microenvironments in the
context of intact immune systems. The ultimate goal is to be able
to mimic, in the mouse, the entire molecular, cellular, tissular and
organic features of human cancers, including their initiation,
progression, evolution, response to therapy, and eventual cure or
relapse. Of course, this is a vicious circle, since there are many things
about human cancer that we still do not understand, so how can
we possibly try to reproduce them? However, we believe that the
quest for the best animal models will be precisely where the answers
to many of the unsolved questions about cancer will be found, and
that the vicious circle will become a virtuous one, since animal
models will provide an invaluable feedback to our understanding
of cancer in the human.
Transgenic mice as model systems: the beginnings
The introduction of transgenic methodology in the cancer field
showed that human oncogenes produce tumors when introduced
into mouse genomic DNA from the germ line (Steward et al., 1982;
Stewart et al., 1984; Adams et al., 1985; Hanahan, 1985; Leder et
al., 1986). These seminal works showed that oncogene expression
is not only required for the initiation of cancer, but also for the
maintenance of the disease, which disappears again when the
inducing stimulus is switched off (Chin et al., 1999; Huettner et al.,
2000; Boxer et al., 2004; Perez-Caro et al., 2007). This has kept
oncogenes firmly in focus as therapeutic targets (Fig. 1). However,
in these early transgenic experiments, the phenotype was highly
influenced by the choice of the attached expression cassette that
regulates when and where the transgene is going to be expressed.
Specifically, in the case of tissue-directed cassettes, they are used
under the assumption that the main bulk of the cellular population
that forms the tumor mass is also the relevant population in terms
of tumor origin. This intuitive observation does not need to be true:
erythrocytes are the most abundant cells in the blood, but they do
not contribute at all to blood regeneration, nor do they carry any
genetic information that is relevant to their function or origin. So,
targeting oncogenes to specific differentiated cell types just because
these cell types are the most abundant ones in the tumor mass does
not need to recapitulate the ontogeny or even the structure of the
tumor (Fig. 1B). Another technical artifact is that, unlike the human
oncogenes, which occur sporadically in single cells during prenatal
or postnatal development, these transgenic mice express the
oncogene in all developing and/or adult cells in which the
expression cassette is active.
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Cancer is a complex and highly dynamic process.
Genetically engineered mouse models (GEMs) that
develop cancer are essential systems for dissecting the
processes that lead to human cancer. These animal
models provide a means to determine the causes of
malignancy and to develop new treatments, thus
representing a resource of immense potential for medical
oncology. The sophistication of modeling cancer in mice
has increased to the extent that now we can induce,
study and manipulate the cancer disease process in a
manner that is impossible to perform in human patients.
However, all GEMs described so far have diverse
shortcomings in mimicking the hierarchical structure of
human cancer tissues. In recent years, a more detailed
picture of the cellular and molecular mechanisms
determining the formation of cancer has emerged. This
Commentary addresses new experimental approaches
toward a better understanding of carcinogenesis and
discusses the impact of new animal models.
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Introducing oncogenes into embryonic stem (ES) cells
to generate dominant mouse mutants: knock-in mouse
models
In order to express the initial oncogenic event in the correct cell
type, one possibility would be to introduce the alteration in the
specific locus of the genome where the wild-type version of the
proto-oncogene or suppressor gene is located, using homologous
recombination in embryonic stem (ES) cells followed by blastocyst
injections to create chimeric mice (Fig. 2). In this way, only a single
copy of the oncogene is expressed and a non-directed restriction
for genome alteration is obtained, so that a limited number of cells
in the organism undergo the genomic alteration, but they can be
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Fig. 1. Main molecular mechanisms of human cancer
and traditional mouse cancer models. (A) Human
cancer is a genetic disease that can originate from several
possible types of alterations affecting the structure and/or
number of oncogenes or tumor suppressor genes.
Independently of the nature of the oncogenic insult, all
human tumor cells carry the oncogenic alteration, from
the cell of origin to the more differentiated cancer cells,
although the role of this oncogene may be different at
different stages of tumor differentiation, and these
mutations might become carrier mutations rather than
driving ones depending on the cellular context. CSC,
cancer stem cells. (B) In the classical transgenic mouse
models of cancer, the oncogene is expressed under the
control of a gene that can be either constitutively
expressed or, alternatively, tissue restricted. In both cases,
all of the cells in the mouse are genetically modified. In
the first case, all of the cells express the oncogene. In the
second case, the oncogene is expressed in all the cells of a
certain chosen tissue. This rather uncontrolled oncogenic
expression leads to the appearance of tumors that do not
necessarily reproduce the hierarchical structure of human
cancers.
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any type of cell. Therefore, if the mutant ES cells have a biased
contribution to the embryo or animal, it can be very informative
about the nature of the defect caused by the cancer gene. Chimera
studies have also been useful in answering the question of whether
the initial oncogenic mutation is sufficient in nature to induce the
tumor phenotype (Castilla et al., 1996; Castellanos et al., 1997;
Yergeau et al., 1997; Okuda et al., 1998; Castilla et al., 1999; Dobson
et al., 1999). A chimera approach was used to investigate the
biological role of the Bcr-ABLp190 and Mll-AF9 oncogenes (Fig. 2B)
(Corral et al., 1996; Castellanos et al., 1997). Both studies
demonstrated oncogenicity and lineage specificity in the chimeric
mice. Despite the activity of the Bcr and Mll endogenous promoters
in a variety of lineages, these mice only developed leukemias, the
specific pathologies that these fusion genes are associated with in
humans (Corral et al., 1996; Castellanos et al., 1997). Thus, these
findings indicated that Bcr-ABLp190 and Mll-AF9 were sufficient
to induce the tumor phenotype when expressed from the correct
endogenous promoters. Similar studies were carried out with the
Aml1-ETO and Cbfb-MYH11 fusions that are associated with
myeloid leukemia (Castilla et al., 1996; Yergeau et al., 1997; Okuda
et al., 1998; Castilla et al., 1999). However, in these cases, the
modified ES cells could not contribute to the hematopoietic
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Fig. 2. Example of the mimicking of a
complex human oncogenic alteration
in the mouse. (A) Molecular mechanism
of a human chromosomal translocation
resulting in a chimeric oncogene.
(B) Knock-in mouse model of
chromosomal translocation. By
homologous recombination in ES cells,
one allele of gene A is modified to
introduce the 3-elements of gene B in
order to mimic the rearrangement seen in
humans. These ES cells are injected into
wild-type (WT) blastocysts to generate
chimeric mice that are composed of WT
and genetically modified cells. Therefore,
a percentage of the cells in every organ of
the chimera carry the oncogenic
alteration, which is expressed under the
regulatory sequences of gene A, thus
generating a model that very closely
mimics the human case where tumoral
cells are mixed in a background of normal
cells. Unfortunately, most of these
chimeric mice cannot produce viable
knock-in offspring, indicating that fusion
proteins are toxic for development.
(C) Conditional, Cre-inducible
translocation model: genes A and B are
modified separately by homologous
recombination in ES cells, and loxP sites
(or the recently developed Dre-rox sites)
are introduced at the precise points
where chromosomal translocation
happens in humans. F1 mice
heterozygous for these modified genes
are generated and crossed with a tissue-
specific Cre (or Dre) recombinase. These
mice carry the modified alleles in all cells
and have no phenotype in the absence of
recombinase. The oncogene is expressed
under the regulatory sequences of gene
A in all the cells expressing recombinase
and their potential descendants. (The
expression of the recombinase under
differentiated cell promoters in
differentiated cells leads to the
appearance of tumors that do not
necessarily reproduce the hierarchical
structure of human cancers.)
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lineages and leukemia did not develop in the chimeric mice
(Castilla et al., 1996; Castilla et al., 1999). Furthermore, all these
knock-in models also presented other complications, mainly the
fact that only the chimeras are viable, and the attempts to obtain
heterozygous descendants through chimera germ line transmission
systematically failed. Altogether, these data demonstrated that the
oncogenicity of some of these fusion genes is restricted to the
context of sporadically acquired mutations and cannot be
reproduced through inherited germ line events.
Conditional knock-in mouse models
Overall, these studies suggested that the leukemia-initiating
genetic events might occur regularly at the stem cell/progenitor
level, irrespective of the phenotypic make-up of the bulk
population of leukemic blasts. An explanation could be that the
oncogene itself determines the differentiation program of the
affected cell clone, which contrasts with the opinion that the
leukemic phenotype is a reflection of the level of the
hematopoietic hierarchy at which the genetic defect occurs.
However, as mentioned previously, germ line mutations do not
allow the correct modeling of sporadic cancer. A solution could
be to restrict the genome alteration, either by limiting the type
and/or number of cells that carry it, or by introducing the genetic
alteration in a silent way that can be activated in a spatial- or
temporal-specific manner. One way to achieve such a model is
the use of an inducible and lineage-specific recombinase (Fig. 2C).
The Cre recombinase of the P1 bacteriophage and the FLP
recombinase of yeast have been the systems of choice for
experiments in mammalian systems. Also, the recently developed
Dre-rox system adds another set of efficient tools that will enable
the generation of more sophisticated mouse models
(Anastassiadis et al., 2009). Using these recombinase-based
systems, recombination/excision results in the creation of specific
inter- or intra-chromosomal rearrangements (Fig. 2C). Thus,
completely normal mice carrying this altered allele in a
heterozygous form can be established. If a transgene expressing
the recombinase under the control of a tissue/cell type-specific
promoter is introduced into this homozygous animal, it will
rearrange both genes in the specifically designed tissue, rendering
the cancer-inducing alteration functional. But, once again, the
final cancer phenotype in these conditional knock-in mouse
models (Johnson et al., 2001; Forster et al., 2003; Grippo et al.,
2003; Coste et al., 2007; Guerra et al., 2007) is influenced by the
tissue-specific nature of the cassette expressing the recombinase
(Fig. 2C).
Stem cells as the cancer-initiating/propagating
population
So clearly, until recently, the main weight of the efforts attempting
to mimic cancer in the mouse have been put on the oncogene’s
side, greatly overlooking the cellular origin of the tumor. This
aspect has been largely taken for granted, always assuming that
the phenotype of the mature tumor cells already implied that the
closest non-pathological relatives to them would be the cells of
origin. It is well established that cancer is a clonal disease that
initiates in a single cell whose progeny make up the tumor.
However, the nature of the cell in which the initiating mutation
occurred in human cancer has received little attention during the
last decades. In recent years, there is growing evidence that stem
cells are the cells of origin for several types of cancer (Bonnet and
Dick, 1997; Cobaleda et al., 2000; Reya et al., 2001; Weissman,
2005; Tan et al., 2006; Ailles and Weissman, 2007; Sanchez-Garcia
et al., 2007; Cobaleda et al., 2008; Vicente-Duenas et al., 2009).
An example is provided by chronic myelogenous leukemia (CML),
a granulocytic disease. However, the BCR-ABL translocation,
which is pathognomonic of this disease, does not arise in a
granulocyte, but rather in a cell at the top of the hematopoietic
differentiation tree (Jamieson et al., 2004). In agreement with this
idea, recent findings suggest that a stem cell constitutes the target
cell in an increasing number of human solid tumors (Al-Hajj et
al., 2003; Singh et al., 2004; Wang et al., 2009).
Much of our current conceptualization of how tumorigenesis
occurs in humans is influenced strongly by mouse models of cancer
development (Sanchez-Martin et al., 2002; Quigley et al., 2009).
Therefore, studies in mice in which the oncogenic alteration(s) is
not directed to the specific cells of origin, as it normally occurs in
most current mouse models, should be interpreted cautiously. The
genetic alterations found in human cancer seem to occur during
specific periods of time and are restricted to a few specific cells.
In several cases, such as in the case of CML, the cancer cell of origin
is a stem/progenitor cell, and this explains the stem cell properties
that allow the cancer stem cells to maintain the tumor mass.
However, there are also many cancers where, most probably, the
cancer cell of origin is a differentiated cell (Cobaleda et al., 2007).
In these cases, the combination of the reprogramming capabilities
of the oncogenic alteration and the intrinsic plasticity of the target
cell (i.e. its susceptibility to the reprogramming) determine the final
outcome of a cancer stem cell. Since not all of the cells present the
same susceptibility to reprogramming, and not all of the oncogenes
possess the same reprogramming capacities (i.e. the ability to confer
stem cell features to the target cell), the targeting of the oncogenic
alteration to the wrong cellular compartment is likely to be a cause
of failure in the generation of accurate mouse models of human
cancer.
Potential solutions: stem cell-activated conditional
knock-in mouse models
Considering these facts, three independent groups have already
shown that the genotype-phenotype correlations found in human
cancer can be established in mice by specific targeting of the stem
cells (Barker et al., 2009; Perez-Caro et al., 2009; Zhu et al., 2009).
In addition to this, it has also been shown that, in the
hematopoietic (Eminli et al., 2009) and nervous (Kim et al., 2009)
systems, the susceptibility of cells to reprogramming is inversely
proportional to their degree of differentiation, and that
hematopoietic stem cells (HSC) are 300 times more prone to be
reprogrammed than B or T cells (Eminli et al., 2009). This stem
cell reprogramming is indeed possible in the case of BCR–ABL-
induced CML, showing that cancer stem cells arise through a
reprogramming-like mechanism and suggesting that the
oncogenes that initiate tumor formation might be dispensable for
tumor progression (Fig. 3A) (Perez-Caro et al., 2009). Using the
Sca-1 promoter as a stem cell-restricted transgenic expression
system, the expression of the oncogene in the reprogramming-
prone stem cells and progenitors allows the development of all
of the cells that compose the tumor mass by a ‘hands-off ’
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mechanism. The modified gene is present in all of the mouse cells,
but the oncogene expression is limited to the stem/progenitor
compartment. This model is very informative with respect to the
fact that the oncogenic mutations can have different roles in
cancer stem cells versus differentiated cancer cells, and explains
why targeted therapies like imatinib can eliminate the latter
without affecting the former. However, once again these GEMs
differ from the real human situation in the fact that, in the human,
all the tumoral cells carry the oncogenic alteration (independently
of the role that this alteration is playing at every stage) (Fig. 1A).
So, clearly, refinements are required. In order to express cancer-
initiating genetic defects randomly in the same target
stem/progenitor cells in which the cancer mutations take place
in humans, we should take advantage once more of conditional
gene targeting approaches but, in this case, in combination with
stem cell-specific promoters (Fig. 3B). Using different conditional
modifications of oncogenes or tumor suppressor genes, in
combination with a stem/progenitor-restricted recombinase, the
oncogenic anomaly is initiated in stem cells and maintained in
all their descendants, in a manner very similar to how it happens
in humans. However, we should be cautious in interpreting the
data, because mouse cells that are used to mimic human disease
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Fig. 3. New approaches to reproduce the hierarchical
structure of human cancer in the mouse. (A) Based on the
reprogramming nature of oncogenes, it has been proven
that restricting the expression of the oncogenic alterations to
the stem cell compartment is all that is needed to
recapitulate all the tumoral heterogeneity. Using a stem cell-
restricted transgenic expression system, the expression of
the oncogene in the reprogramming-prone stem cells and
progenitors allows the development of all the cells that
compose the tumor mass by a ‘hands-off’ mechanism. The
modified gene is present in all the mouse cells but
expression of the oncogene is limited to the stem/progenitor
compartment. (B) Conditional activation of an oncogenic
alteration from the stem cell onwards: by using a
conventional transgene that can be activated by
recombinase, with the regulatory sequences of a constitutive
or tissue-restricted gene (B1); by modifying the locus of an
oncogene by introducing a recombinase-inducible
activating mutation (B2) or, by modifying the locus of a
tumor suppressor to achieve a recombinase-mediated
deletion (B3). In these three cases, in combination with a
stem/progenitor-restricted recombinase, the oncogenic
anomaly is initiated in stem cells and maintained in all their
descendants in a manner that is very similar to how it
happens in humans.
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are more prone to transformation than human cells and, thus,
one mutation can lead to full-blown cancer in the mouse
transgenic model but not in humans. Furthermore, the regulation
of certain genes/pathways might differ between mouse and
human.
Outlook
The recent discoveries that crucial genetic events take place within
somatic primitive cells in some human cancers have led to
enthusiasm within the scientific community for generating cancer
mouse models that accurately reflect the genotype-phenotype
correlation seen in human cancer. These future mouse cancer
models are needed as a source for dissecting the genomic pathways
that feed these cancers and for the discovery of new therapeutic
leads. The challenge of the next decade is to define cancers
according to their unique molecular alterations and to treat them
accordingly. These recent discoveries will allow the translation from
modern genetic laboratory tools to advances that will improve the
lives of cancer patients.
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